Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants w
...
ho received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
In resource restriced countries
OpenWHO is an interactive, web-based, knowledge-transfer platform offering free online courses to improve the response to health emergencies. COVID-19 resources are available in the official WHO languages and in additional national language
...
s .The OpenWHO team is continuing to work with WHO Country Offices, public health institutes and educational entities who haveoffered voluntary translation support to help localize the response efforts. Resources in the pipeline include courses in Hindi and Macedonian.
more
This course provides information on what facilities should be doing to be prepared to respond to a case of an emerging respiratory virus such as the novel coronavirus, how to identify a case once it occurs, and how to properly implement IPC measures to ensure there is no further transmission to HCW
...
or to other patients and others in the healthcare facility. This course has been updated in January 2022 and highlights the latest WHO guidance to date. Please note that our guidance is continuously being updated and the other language versions of the course will gradually be updated too.
This training is intended for healthcare workers and public health professionals, as it is focused on infection prevention and control.
This course is also available in the following languages:
русский - 日本語 - français - Bahasa Indonesia - Español - Português - Italiano - српски језик - 中文 - македонски јазик - Türkçe - język polski - Tiếng Việt - العربية - Nederlands - Tetun - বাংলা - فارسي - Soomaaliga
more
A range of learning resources for primary health care of the newborn are available
This course consists of a video which provides an introduction to COVID-19 in Indian Sign Language.
Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Res
...
piratory Syndrome (SARS).
A novel coronavirus (COVID-19) was identified in 2019 in Wuhan, China. This is a new coronavirus that has not been previously identified in humans.
This course consists of a video which provides an introduction to COVID-19 in Indian Sign Language.
more
AstraZeneca-SKBio in South Korea and Serum Institute of India
Coronavirus disease (COVID-19) science conversation
In this video and audio series WHO experts explain the science related to COVID-19. This series is available every week on WHO's YouTube, Instagram, Facebook, Twitter, and LinkedIn channels and on all major podcasts platforms.
Download all epis
...
ode transcripts in Arabic, Chinese, English, French, Portuguese, Russian, Spanish, Hindi, Maithili, Nepali
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant]
...
vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
The meeting of leprosy programme managers in the South-East (SE) Asia Region was convened by the WHO Regional Office for South-East Asia (WHO-SEARO) from 11 to 13 April 2023 in Kolkata, India. The meeting was attended by 40 participants, including 1
...
5 national focal points from nine countries, five experts, partners, donors and WHO staff members, including those from the Global Leprosy Programme (GLP).
The objectives of the meeting were to:
- review the current situation and progress of leprosy elimination in the Member States;
- discuss the updates on the new guidance and tools from the Global Leprosy Programme;
- facilitate experience-sharing and catalyse discussions to identify innovative practices, solutions and remaining gaps across countries to enhance leprosy elimination activities; and
- determine priority actions and support needs for accelerating leprosy elimination in the Region.
more
This mapping aimed at understanding the profile, activities, needs and priorities of civil society organizations of relevance to NCDs and their risk factors, and exploring their scope to improve their response to the issue.
Nepal is the world’s third most polluted country. Air pollution shortens average Nepalese life expectancy by 4.1 years, relative to what it would be if the World
...
Health Organization (WHO) guideline of 5 μg/m3 was met.1 The highest concentrations of air pollution are observed in Nepal’s southwestern districts, which share their borders with the highly-polluted Indo-Gangetic Plain of India. Here, residents stand to lose nearly 7 years of life expectancy.
more